Tiefenbacher Group greetings from DCAT Week!
March 21, 2024
Today is the last day of one of the world´s most important pharma events – DCATWeek in New York City!Our Tiefenbacher Group team sends greetings and their impressions of DCAT Week from…
Tiefenbacher Group awarded EcoVadis silver medal!
March 19, 2024
We are excited to share that Tiefenbacher API + Ingredients has been awarded the EcoVadis Silver Medal!EcoVadis is the world’s largest provider of business sustainability ratings. The EcoVadis…
Tiefenbacher Group celebrates International Women’s Day
March 8, 2024
Today Tiefenbacher Group celebrates International Women's Day, that's why we would like to introduce you to two valuable female employees from our company.Get to know the women who are working at…
Tiefenbacher Group on awareness for rare disease day
February 29, 2024
Tiefenbacher Group draws attention to Rare Disease Day.Today we are focusing on awareness and generating change for the 300 million people worldwide living with rare diseases. Treatment for many rare…
Tiefenbacher Group supports Pharmacists in Ukraine
February 24, 2024
Tiefenbacher Group supporting people in Ukraine by donating to Pharmacists without borders.The 24 February 2024, marks the second anniversary of the brutal Russian war against a sovereign Ukraine.…
Tiefenbacher Group renovation of headquarters
February 14, 2024
Tiefenbacher Group keeping you updated on the ongoing renovation of our headquarters at the Port of Hamburg in Germany.Tiefenbacher Group is happy to present some of the results of the remodelling…
Tiefenbacher Group wishes a Happy Chinese New Year!
February 9, 2024
The Chinese New Year is almost here.On the 10th of February, people around the world celebrate the Chinese New Year. They honour this day with carnival events, family gatherings, parades, traditional…
Tiefenbacher Group together against blood cancer
January 25, 2024
Tiefenbacher Group and DKMS together against blood cancer!We are pleased to inform you that we have initiated a DKMS registration event during the last week in our headquartes in Hamburg to look for…
Tiefenbacher speaks out against racism and supports diversity
January 23, 2024
Tiefenbacher Group speaks out against racism and supports diversityTiefenbacher recognises its responsibility to be a force for good with its pharmaceuticals. Additionally our wider actions aim to…
Tiefenbacher Group AET Laboratories 20th anniversary celebration
January 3, 2024
AET Laboratories 20th anniversary celebration was a tremendous success!Last year, we not only celebrated Tiefenbacher Group´s 60th anniversary in Hamburg, but also the 20th…
Tiefenbacher Group wishes you a happy new year!
January 1, 2024
As 2023 draws to a close, the Tiefenbacher Group would like to share some of the year's highlights with you. This year we not only had our 60th anniversary to celebrate, but also many…
Tiefenbacher New Market Launch: Rivaroxaban in Canada
November 16, 2023
Tiefenbacher Pharmaceuticals successfully launches the anticoagulant Rivaroxaban on day one in CanadaWe at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be…
Tiefenbacher Group 60 years of pioneering healthcare!
October 19, 2023
60 years of pioneering healthcare at Tiefenbacher GroupTiefenbacher Group says “Thank you” to our colleagues from our three main locations in Hamburg (Germany), Hyderabad…
Tiefenbacher Group 60 years anniversary celebration!
October 12, 2023
60 years anniversary celebrationsWe are very happy to announce that Tiefenbacher Group celebrates its 60th anniversary this year! 60 years ago, our founder and pioneer Alfred E.…
Tiefenbacher Group sustainable impact in Hyderabad/India
September 29, 2023
Tiefenbacher Group relocation of trees in Hyderabad – contribution to our India community to make life better for people and planetAt Tiefenbacher Group, we know that our responsibility as a global…
Tiefenbacher New Market Launch: generic launch Teriflunomide
September 27, 2023
New market launch: Tiefenbacher Pharmaceuticals successfully launches the generic version of Teriflunomide in more than 20 European countriesTiefenbacher Pharmaceuticals has successfully prepared a…
State-of-the-art R&D facilities for powerful drug development
July 21, 2023
State-of-the-art R&D facilities for powerful drug development and manufacturing. New technology for generic, valued added, and innovative pharmaceuticalsWe, at Tiefenbacher Group, go beyond…
Tiefenbacher Group Social Day 2023: Community Engagement
June 29, 2023
Tiefenbacher Group Social Day 2023 – contribution through our social and community engagement in HamburgTiefenbacher Group employees get involved in the local community by volunteering with local…
Tiefenbacher Community engagement: School in Hyderabad /India
June 28, 2023
Tiefenbacher Social Responsibility & Community engagement: New School in Hyderrabad /India – taking action to ensure a positive impact for children and a better future Tiefenbacher…
TIEFENBACHER API + INGREDIENTS offers Raw Material for Animal Health
June 16, 2023
TIEFENBACHER API + INGREDIENTS offers Raw Material for Animal Health: Companion and Farm AnimalsDid you know that Tiefenbacher API + Ingredients offers in addition to its extensive…
OYSTA: Launch of new OYSTA website
June 6, 2023
Launch of new OYSTA websiteWe are happy that we have launched a new web page for OYSTA – an innovative healthcare brand which we have developed together with our partner OnDosis. With…
SFDA approves Tiefenbacher facilities
May 10, 2023
Tiefenbacher: Own manufacturing and laboratory facilities successfully registered by the Saudi Food and Drug Authority (SFDA) for GCC regionThe SFDA approves Tiefenbacher facilities! We are happy to…
Tiefenbacher Group is committed to becoming climate neutral
April 28, 2023
Tiefenbacher Group is committed to becoming climate neutral by the end of 2025 - sustainability contribution to make life better for people and planetWe are pleased to share that TIEFENBACHER GROUP…
Tiefenbacher Group: Renovating Headquarters in Hamburg
April 21, 2023
Tiefenbacher Group: Renovating Headquarters in Hamburg /Germany – an agile, open-plan work spaceTiefenbacher Group is renovating the Headquarters in Hamburg for flexible working while…
Tiefenbacher Group at DCAT week 2023
March 27, 2023
Tiefenbacher Group at DCAT 2023 – Thanks for meeting us in New York City!It has been four very successful and inspiring days for TIEFENBACHER GROUP in New York City. We were delighted…
Tiefenbacher Generic Launch: antihistamine Bilastine
March 14, 2023
Generic Launch: Tiefenbacher Pharmaceuticals successfully launches the antihistamine Bilastine for a market entry as over-the-counter (OTC) medicine in germanyGeneric drugs: As the allergy season is…
Tiefenbacher registered by United Arab Emirates Ministry of Health
February 25, 2023
Tiefenbacher Group manufacturing sites have been successfully registered by the United Arab Emirates Ministry of HealthThe Tiefenbacher Group is very excited to announce that our two manufacturing…
Tiefenbacher marks World Cancer Day 2023
February 3, 2023
TIEFENBACHER marks 'World Cancer Day 2023' to increase awareness prevention throughout media togetherTIEFENBACHER joined to harness the power of social media to raise awareness on cancer early…
Tiefenbacher Group wishes a happy Chinese New Year 2023!
January 22, 2023
We at Tiefenbacher Group appreciate the diversity of our colleagues very much and are happy to celebrate their local traditions together. This year, on the 22nd of January, people…
Tiefenbacher Group wishes a healthy New Year 2023
January 3, 2023
From all over the world, we wish you a happy and healthy New Year 2023!Tiefenbacher Group wishes a everyone a healthy New Year. We hope the year 2023 will be as successful and full of…
Tiefenbacher Pharmaceuticals New Market Launch: Apremilast (Psoriasis)
December 1, 2022
New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the psoriasis medication Apremilast in CanadaWe at Tiefenbacher Pharmaceuticals strive to make our…
Tiefenbacher Pharmaceuticals New Market Launch: Abiraterone for prostate cancer
November 17, 2022
New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launces generic version of the prostate cancer medicines Abiraterone and the value-added product Abiraterone/PrednisoloneWe at…
Thanks for visiting us at CPhI 2022 in Frankfurt!
November 10, 2022
Tiefenbacher Group: Three Successful Days at CPhI 2023 - Thank you for visiting us in Barcelona!
TIEFENBACHER GROUP opens new manufacturing site in Cyprus
October 28, 2022
TIEFENBACHER GROUP opens new manufacturing site in Cyprus for drug production of high-quality pharmaceuticals – we continuously expand in novel technologies and capabilities to improve quality and…
Tiefenbacher Pharmaceuticals New Market Launch: Apixaban anticoagulant
October 20, 2022
New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the anticoagulant medicine Apixaban in CanadaWe at Tiefenbacher Pharmaceuticals are driven by enabling people…
Meet TIEFENBACHER GROUP at CPhI 2022 in Frankfurt /Germany
October 4, 2022
Meet TIEFENBACHER GROUP at CPhI in Frankfurt from 1-3 Nov and discover our latest ideas to make pharmaceuticals more affordable, more available, and better than before!We are very excited to meet our…
Tiefenbacher Pharmaceuticals New Market Launch: Vildagliptin/Metformin
September 8, 2022
NEW Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the diabetes medicine Vildagliptin and Vildagliptin /Metformin in AfricaWe at Tiefenbacher Pharmaceuticals…
Tiefenbacher: Employee benefits and climate reduction goals
August 18, 2022
Environmentally friendly and health-promoting: TIEFENBACHER GROUP offers bike leasing to employeesEmployees benefits while reducing our impact on the environment with climate reduction goals – we…
Tiefenbacher Pharmaceuticals New Market Launch: Rivaroxaban
July 15, 2022
Global market launch: TIEFENBACHER PHARMACEUTICALS expands the launch of the anticoagulant medicine Rivaroxaban to Central America and further international marketsWe at Tiefenbacher Pharmaceuticals…
Tiefenbacher Pharmaceuticals New Market Launch: Teriflunomide
June 1, 2022
NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES FIRST GENERIC VERSION OF THE MULTIPLE SCLEROSIS MEDICINE TERIFLUNOMIDE IN CANADAWe at Tiefenbacher Pharmaceuticals strive to make…
Sustainability: TIEFENBACHER GROUP becomes member of the Pharmaceutical Supply Chain Initiative (PSCI)
May 24, 2022
TIEFENBACHER GROUP becomes member of the Pharmaceutical Supply Chain Initiative (PSCI) – contribution to make life better for people and planetWe at TIEFENBACHER GROUP are committed to promote…
TIEFENBACHER GROUP OPENS NEW SITE FOR HIGHLY POTENT DRUGS IN INDIA
May 5, 2022
TIEFENBACHER GROUP opens new site for highly potent drugs in India – we continuously expand in novel technologies and capabilities to improve quality and boost productivity of better…
WORLD HEALTH DAY @ TIEFENBACHER GROUP
April 7, 2022
World Health Day is on the 7th of April each year – this day marks the anniversary of the World Health Organization which was founded in 1948.Today we celebrate World Health Day. This Day marks the…
TIEFENBACHER AT DCAT 2022 IN NEW YORK CITY! – Thanks for Meeting us
March 29, 2022
TIEFENBACHER GROUP AT DCAT 2022 – THANKS FOR MEETING US IN NEW YORK CITY! One of the world´s most important pharma events – DCAT-Week in New York City – has just come to an end. It was…
Tiefenbacher Pharmaceuticals New Market Launch: Lacosamide
March 22, 2022
NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES FIRST GENERIC VERSION OF THE EPILEPSY MEDICINE LACOSAMIDE IN AUSTRALIAWe at Tiefenbacher Pharmaceuticals strongly believe that…
TIEFENBACHER GROUP stands with UKRAINE
March 9, 2022
Peace and freedom for Ukraine: We, a healthcare company in Europe, stand in solidarity with the people in UkraineTo us at Tiefenbacher Group, it is unbearable to witness what is happening in Ukraine.…
MEET TIEFENBACHER GROUP DURING DCAT WEEK IN NEW YORK CITY 2022
February 9, 2022
Meet TIEFENBACHER GROUP during DCAT week in New York City 2022 from 21-24th march!Reach out to TIEFENBACHER GROUP at DCAT in New York City from 21-24th March and discover our latest ideas to make…
TIEFENBACHER GROUP WISHES A HAPPY AND HEALTHY NEW YEAR 2022 FROM ALL OVER THE WORLD!
January 4, 2022
We at TIEFENBACHER GROUP wish you a happy and healthy new year 2022 from all over the world! Please watch the short video for our new year greetings from our colleagues from our three…
TIEFENBACHER GROUP enlarges its manufacturing facilities in India and Cyprus
December 15, 2021
Driving efficiency is our key – TIEFENBACHER GROUP enlarges its manufacturing facilities in India and Cyprus for powerful drug productionDid you know that TIEFENBACHER GROUP heavily invests in its…
TIEFENBACHER GROUP at CPhI 2021 in Milano – thank you for visiting us!
November 17, 2021
Tiefenbacher Group: Three Successful Days at CPHI 2021 in Milano - Thank you for visiting usWith over 1,300 exhibitors and more than 20,000 attendees the world`s leading pharma eventt…
TIEFENBACHER GROUP: New school building in India
October 25, 2021
At TIEFENBACHER GROUP giving back to society is important to us: New school building in India As a value-driven healthcare company, dedicated to improve the life of patients worldwide,…
TIEFENBACHER GROUP at CPhI in Milan 2021
October 6, 2021
Reach out to the TIEFENBACHER GROUP at CPHI in Milan 2021 and discover our latest innovations to make pharmaceuticals more affordable, more available, and better than before.“Nothing can replace…
Tiefenbacher Pharmaceuticals: Launch of first generic version of the antihistamine Bilastine
September 20, 2021
New market launch: TIEFENBACHER PHARMACEUTICALS successfully launches first generic version of the antihistamine BilastineWe at Tiefenbacher Pharmaceuticals strongly believe that our high-quality…
New agreement expands collaboration between OnDosis and TIEFENBACHER GROUP
May 26, 2021
Innovative Healthcare Pharmaceuticals with e-health technology in the ADHD field, rare diseases, and transplantation medicineSwedish Life science company OnDosis and German B2B pharmaceutical company…
TIEFENBACHER GROUP supports Post COVID-19 with Posaconazole against Black Fungus (Mucormycosis)
May 19, 2021
TIEFENBACHER GROUP supports Post COVID-19 with Posaconazole tablets against Black Fungus (Mucormycosis) in IndiaBlack Fungus (Mucormycosis) is dramatically spreading in India connected to the…
TIEFENBACHER GROUP announces global launch of TIEFENBACHER MEDICAL DEVICES
April 16, 2021
Innovation healthcare by combining established drug-based medicines with medical devices and digital healthAfter more than five years in operation, TIEFENBACHER GROUP transfer its medical device…
TIEFENBACHER API + INGREDIENTS: FIRST API BASED ON GREEN CHEMISTRY
April 15, 2021
TIEFENBACHER API + INGREDIENTS starts to offer the first API based on green chemistryWe at TIEFENBACHER API + INGREDIENTS are committed to drive greem chemistry in the pharmaceutical raw material…
TIEFENBACHER PHARMACEUTICALS: Launch of generic version of Teriflunomide, Multiple Sclerosis (MS)
February 23, 2021
TIEFENBACHER PHARMACEUTICALS announces global generic launch of Teriflunomide – making multiple sclerosis therapy more affordable and better available worldwideTiefenbacher Pharmaceuticals has…
AET Pharma US Inc., Part of Tiefenbacher, approval of Abbreviated New Drug Application (ANDA) for Posaconazole
February 8, 2021
AET Pharma US Inc. announces successful approval of Abbreviated New Drug Application (ANDA) for PosaconazoleOn 1st February 2021, AET Pharma US Inc, part of TIEFENBACHER GROUP, received FDA approval…
TIEFENBACHER PHARMACEUTICALS: Launch of Rivaroxaban
January 26, 2021
TIEFENBACHER PHARMACEUTICALS announces global launch of Rivaroxaban – an anticoagulant medication (blood thinner)Tiefenbacher Pharmaceuticals, part of Tiefenbacher Group, is pleased to announce the…
International Brand Relaunch of Tiefenbacher Group
October 2, 2020
Tiefenbacher Group: Improving people’s life by making pharmaceuticals more affordable, more available, and better than before“We are very excited to launch the new Tiefenbacher Group website.…
Tiefenbacher Group and OnDosis enter a partnership for medicines and digital health
September 10, 2020
Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’…